SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Human Genome Sciences, Inc. (HGSI)
An SI Board Since March 1996
Posts SubjectMarks Bans Symbol
1127 105 0 HGSI
Emcee:  Jeffrey Ogbar Type:  Unmoderated
Introduction Market Data Compact
Hey, what's going on here? HGSI is supposed to be the next Wal Mart,
Coca-Cola in 1900, and all these great possibilities in its embryonic
stages. I understand that HGSI holds more data and research on genes
than all other such companies combined! Why, then, is the stock sliding
down?

Jeff
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1127GlaxoSmithKline (LSE:GSK) today announced top-line results from the Phase III STnigel bates-11/12/2013
1126Do I get to turn out the lights?Steven Rachbach-7/20/2012
1125HGSI is trading about 10% above Human Genome Sciences' bid: GlaxoSmithKlineGlenn Petersen-4/19/2012
1124Is this ready to turn? Last sold at a LOSS is Dec 04 at $11.71. What do you thsteve kammerer-1/23/2012
1123 Human Genome Sciences Reports Progress with Commercialization of BENLYSTAPaul Lee-1/9/2012
1122Stock has been halted, pending decision, which is now in: Benlysta approved. Chtuck-3/9/2011
1121Human Genome Sciences, Las Vegas Sands: Intellectual Property By Victoria Slind-Paul Lee-1/27/2011
1120AC recommends Benlysta 13-2. Up almost 20% AH, last trade up 10%. After HoursIan@SI-11/16/2010
1119Glaxo, Human Genome Lupus Medicine May Not Be Safe, FDA Staff Report Says By Moltnsaf-11/12/2010
1118Didn't take the first loss and expected to regret it bitterly. Astounding.tom pope-11/16/2009
1117Shouldn't have cut it off where I did. <i>“We have responded to all otom pope-11/16/2009
1116ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI - Newtom pope-11/16/2009
1115And the volume is a lot more respectable at nearly 700k.tom pope-11/2/2009
111435+ percent now. JonRobohogs-11/2/2009
1113Good for 23%, but on very few shares traded.tom pope-11/2/2009
1112ROCKVILLE, Md. & LONDON--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdanigel bates-11/2/2009
1111See bolded. It was down during the day, quite significantly, but up a tad after tom pope-10/24/2009
1110Thomas Weisel conference, 9/9/09 There is never any big news at one of these cSteven Rachbach-9/9/2009
1109The interim "independent analyses" will most likely not provide unblinkenhott-8/28/2009
1108From the GSK PR: <<The study will be stopped when approximately 1500 repoSteven Rachbach-8/27/2009
1107UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study ikenhott-8/27/2009
1106The darapladib trial is a blinded trial. So GSK would only see the blended datakenhott-8/27/2009
1105Given the interest in a possible buyout by GSK, the brief portion of this webcasDewDiligence_on_SI-8/26/2009
1104Ken, You are plenty smart. A couple of comments: <<Darapladib is a highSteven Rachbach-8/26/2009
1103And now rumor is there is no buyout forthcoming!! This market is crazy. Nice worrkrw-8/26/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News